Biocept's cerebrospinal fluid test improves cancer detection vs standard cytology

• Provider of cancer molecular tests, Biocept (NASDAQ:BIOC) has announced results from a prospective study comparing its Target Selector cerebrospinal fluid testing to conventional cytology in with non-small cell lung cancer and leptomeningeal metastasis. The results were presented at the International Association for the Study of Lung Cancer. Have a look at the presentation here.
• In this study, 28 cerebrospinal fluid samples from 15 patients obtained sequentially before and during treatment were compared. Target Selector improved detection of circulating tumor cells (CTC), finding CTCs in 78% of the samples, whereas cytology detected tumor cells in 55% of samples.
• Target Selector also provided sensitive quantitative identification of actionable EGFR mutations in cerebrospinal fluid.
• Also, alterations in CTC density as well as in EGFR mutant copy numbers were observed weeks before a treatment response was measured via traditional clinical evaluations.
• https://seekingalpha.com/news/3619752-study-shows-biocepts-cerebrospinal-fluid-test-improves-cancer-detection-compared-to-standard